Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
The purpose of this study is partly to continue the good experience the investigators have with chemotherapy and partly to optimize treatment of inoperable cholangiocarcinoma by adding a biological antibody to the treatment of patients with wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS).
详细描述
Cholangiocarcinoma is a relatively rare disease. In Denmark approximately 150 patients are diagnosed each year. A small part of the patients can be offered surgery, but the operation will rarely be radical, and most patients with cholangiocarcinoma are therefore candidates for chemotherapy.
In Denmark the combination therapy of Gemcitabine, Oxaliplatin and Capecitabine has been used in recent years. Based on experience with gastrointestinal tumors, however, there seems to be an effect of new biological substances, including EGFR antibodies. There are casuistic reports on the specific effect of a monoclonal antibody against EGFR in cholangiocarcinoma.
The effect of EGF is mediated through an intracellular pathway involving the KRAS protein. It has been shown that a mutation of KRAS causes the EGF system to be constantly activated. Effect in patients with a KRAS mutation is therefore not to be expected. Approximately 50% of the patients present this mutation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically verified adenocarcinoma arisen from gallbladder, extra or intrahepatic bile ducts or malignant cells consistent with the above and concomitant radiologic findings consistent with cholangiocarcinoma.
- •Curative treatment presently discounted (surgery, stereotactic radiotherapy, etc.)
- •KRAS analyzed and found wild-type (wt) or mutated
- •Evaluable disease according to RECIST criteria, i.e., the disease does not need to be measurable
- •Haematology:
- •ANC ≥ 1.5 x 10^9/l
- •Thrombocytes ≥ 100x10^9/l
- •Biochemistry:
- •Bilirubinaemia ≤ 3 x upper normal value
- •ALAT ≤ 5 x upper normal value
- •Creatinin ≤ upper normal value. If raised creatinin, the measured or calculated GFR must be at least 50% of the lower normal value.
- •Fertile women must present a negative pregnancy test and use birth control during and 3 months after treatment. The following methods are considered safe birth control: Birth control pills, coil, gestagen deposit injection, subdermal implantation, hormonal vagina ring, and transdermal deposit band-aid)
- •Oral and written informed consent
排除标准
- •Chemotherapy within 4 weeks
- •Radiotherapy within 4 weeks
- •Immunotherapy within 4 weeks
- •Other concomitant experimental treatment
- •Known neuropathy ≥ grade 2
- •Serious congruous medical disease
- •Other previous malignant disease within 5 years, excl. non-melanoma skin cancer and carcinoma in situ cervicis uteri
- •Previous serious and unexpected reactions to fluoropyrimidine treatment
- •Hypersensitivity to one or more of the active substances, auxiliary substances or fluoruracil
- •Patients with interstitial pneumonitis or pulmonary fibrosis
研究组 & 干预措施
KRAS wildtype
干预措施: Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine (Drug)
KRAS mutation
Inclusion has been completed in the KRAS mutation arm.
干预措施: Gemcitabine, Oxaliplatin, Capecitabine, (Drug)
结局指标
主要结局
Progression free survival
时间窗: Up to 6 months
次要结局
- Response rate(6 months)
- Overall survival(6 months.)